Concert Pharmaceuticals' once-a-day candidate begins trials; Study supportive of Genentech's injectable eye drug;

> Concert Pharmaceuticals announced it has begun Phase I study of its candidate for cystic fibrosis, which it hopes will enable once-a-day dosing. More

> A study in the Journal of the American Medical Association found that injection of Genentech's eye drug Lucentis performed noninferiorly to a laser-based procedure treating diabetic retinopathy. More